Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients
Shafiee et al., Virology Journal, doi:10.1186/s12985-022-01829-8
Shafiee et al., Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of.., Virology Journal, doi:10.1186/s12985-022-01829-8
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Meta analysis including 17 of 95 studies (45 RCTs), finding significantly lower mortality with ivermectin. All seven outcomes favor ivermectin, while statistical significance is reached only for mortality. The conclusion is incorrect, authors find significantly lower mortality. Authors suggest lower risk of bias studies show lower effects, however their analysis is unreliable. For example consider Reis et al., authors give the study a perfect rating in risk of bias analysis, however this study not only has a very high theoretical risk of bias, but shows very high actual bias, randomization failure, blinding failure, and reports conflicting data that is impossible to be correct [Reis].
Currently there are 95 ivermectin studies and meta analysis shows:
OutcomeImprovement
Mortality51% lower [37‑62%]
Ventilation29% lower [13‑42%]
ICU admission41% lower [16‑58%]
Hospitalization34% lower [20‑45%]
Cases78% fewer [67‑85%]
Shafiee et al., 13 Jun 2022, peer-reviewed, 6 authors.
Contact: hamidrezamozhgani@gmail.com (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: (2022) 19:102 Shafiee et al. Virology Journal https://doi.org/10.1186/s12985-022-01829-8 Open Access RESEARCH Ivermectin under scrutiny: a systematic review and meta‑analysis of efficacy and possible sources of controversies in COVID‑19 patients Arman Shafiee1,2, Mohammad Mobin Teymouri Athar3, Omid Kohandel Gargari1, Kyana Jafarabady1, Sepehr Siahvoshi4 and Sayed‑Hamidreza Mozhgani5,6* Abstract Background: We conducted a systematic review and meta-analysis to evaluate the efficacy of ivermectin for COVID19 patients based on current peer-reviewed RCTs and to address disputes over the existing evidence. Methods: MEDLINE (Pubmed), Scopus, Web of Science, Cochrane library, Google scholar and Clinicaltrials.gov were searched for RCTs assessing the efficacy of Ivermectin up to 20 February 2022. A systematic review and meta-analysis of studies was performed based on the PRISMA 2020 statement criteria. Results: 19 and 17 studies were included in this systematic review and meta-analysis, respectively. There was no significant difference in progression to severe disease (log OR − 0.27 [95% CI − 0.61 to 0.08], I2 = 42.29%), nega‑ tive RT-PCR (log OR 0.25 [95% CI − 0.18–0.68], I2 = 58.73%), recovery (log OR 0.11 [95% CI − 0.22–0.45], I2 = 13.84%), duration of hospitalization (SMD − 0.40 [95% CI − 0.85–0.06], I2 = 88.90%), time to negative RT-PCR (SMD − 0.36 [95% CI − 0.89–0.17], I2 = 46.2%), and viral load (SMD -0.17 [95% CI -0.45 to 0.12], I^2 = 0%). It is worth noting that, based on low-certainty evidence, ivermectin may possibly reduce mortality (log OR − 0.67 [95% CI − 1.20 to − 0.13], I2 = 28.96%). However, studies with a higher risk of bias were more likely to indicate positive effects on the efficacy of this drug, according to our subgroup analyses based on study quality. Conclusion: Ivermectin did not have any significant effect on outcomes of COVID-19 patients and as WHO recom‑ mends, use of ivermectin should be limited to clinical trials. Keywords: COVID-19, SARS-CoV-2, Ivermectin, Treatment, Meta-analysis, Mortality
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit